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Correlation of Infinium HumanMethylation450K and MethylationEPIC BeadChip
arrays in cartilage
Kathleen Cheung a,b, Marjolein J. Burgersa, David A. Young a, Simon Cockellb, and Louise N. Reynarda
aSkeletal Research Group, Institute of Genetic Medicine, Newcastle University, Central Parkway, Newcastle upon Tyne, UK; bBioinformatics
Support Unit, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK
ABSTRACT
DNA methylation of CpG sites is commonly measured using Illumina Infinium BeadChip platforms.
The Infinium MethylationEPIC array has replaced the Infinium Methylation450K array. The two
arrays use the same technology, with the EPIC array assaying almost double the number of sites
than the 450K array. In this study, we compare DNA methylation values of shared CpGs of the
same human cartilage samples assayed using both platforms. DNA methylation was measured in
21 human cartilage samples using the both 450K and EPIC arrays. Additional matched 450K and
EPIC data in whole tumour and whole blood were downloaded from GEO GSE92580 and
GSE86833, respectively. Data were processed using the Bioconductor package Minfi. DNA methy-
lation of six CpG sites was validated for the same 21 cartilage samples by pyrosequencing. In
cartilage samples, overall sample correlations of methylation values between arrays were high
(Pearson’s r > 0.96). However, 50.5% of CpG sites showed poor correlation (r < 0.2) between arrays.
Sites with limited variance and with either very high or very low methylation levels in cartilage
exhibited lower correlation values, corroborating prior studies in whole blood. Bisulphite pyrose-
quencing did not highlight one array as generating more accurate methylation values. For
a specific CpG site, the array methylation correlation coefficient differed between cartilage,
tumour, and whole blood, reflecting the difference in methylation variance between cell types.
Researchers should be cautious when analysing methylation of CpG sites that show low methyla-
tion variance within the cell type of interest, regardless of the method used to assay methylation.
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Introduction
Illuminamethylation BeadChip arrays are a popular
method for assaying methylation of CpG sites
across the human genome. In 2016, the Illumina
MethylationEPIC (EPIC) array replaced the
Methylation450K (450K) array, which has since
been discontinued. The EPIC array uses the same
Infinium probe technology and shares 452,453
common probes, but assays almost double the num-
ber of CpG sites compared to the 450K array. The
450K and EPIC arrays utilize Infinium type I and
type II probes. Type I probes consist of two probes,
each binding to either methylated or unmethylated
sites, whereas type II probes use one probe to bind
to the target CpG. Type I probes are reported to be
more effective at assaying completely un-
methylated or completely methylated probes [1].
The combination of type I and type II probes
ensures that the whole range of methylation value
can be assayed genome wide. The same CpG is
assayed by the same probe type on both arrays;
sites do not change probe chemistries between
arrays; a comprehensive description of probe types
is available [2]. As ongoing studies and meta-
analyses may use data from both array platforms,
previous studies have assessed the concordance of
the two by correlating methylation levels of the
same samples assayed on both arrays. Studies com-
paring the two arrays have been reported in tumour,
whole blood, and placental samples [3–6]. Whilst
high overall per sample correlations (Pearson’s r >
0.9) were reported, two of the blood studies found
that many individual sites in whole blood showed
poor correlations (r < 0.2) [2,3]. The studies in
whole blood suggested that CpG sites with low
variance and that are either completely methylated
or un-methylated tend to exhibit a poor correlation
between 450K and EPIC arrays. Furthermore,
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several studies have highlighted sites with low cor-
relation in blood and placental tissue that they have
recommended be removed from the analysis when
performing a meta-analysis of 450K and EPIC data-
sets [3–5].
In this study, we investigate the correlation of the
450K and EPIC platforms in human cartilage, a tissue
which comprises a single cell type. As variance of
DNA methylation in single CpG sites has been
found to affect correlation across 450K and EPIC
arrays, we hypothesize that tissue types with different
inherent DNA methylation variances do not have the
same correlation across the two arrays. Tumour tissue
is heterogeneous and whole blood consists of many
cell types, factors which affect the variance of DNA
methylation of CpG sites in a sample. We assayed 21
cartilage samples on both BeadChip arrays and exam-
ined per sample and per CpG correlations. We also
downloaded publicly available 450K and EPIC data in
whole tumour (GEO GSE92580) and whole blood
(GSE86833) to compare the variance and correlation
across arrays with cartilage samples. We sought to
investigate the accuracy of array generated methyla-
tion values for six CpG sites using the gold standard of
bisulphite pyrosequencing in the 21 samples common
to both arrays.
Results
Overall sample correlation between 450K and
EPIC arrays
DNA methylation in human cartilage samples, 9
from patients undergoing total joint replacement
with osteoarthritis (OA) of the knee and 12 with
neck of femur fracture (NOF), was assessed using
the 450K and EPIC arrays. The correlation between
the same samples ran on both arrays was examined,
with probes common to both arrays included in the
analysis. In total, 450K and EPIC share 452,453
probes. Quality control measures and probe filters
including removal of sex chromosome and cross-
reacting probes were applied to ensure only probes
which could be measured with confidence were
used for further analysis (see Methods section).
After quality control of probes, 370,669 remained.
Additionally, all cartilage samples had >95% probes
with a detection p value <0.01 on both 450K and
EPIC arrays. Both arrays were normalized using the
functional normalization method [7], which uses
control probes to account for unwanted variation
in the data.
To investigate the correlation between the arrays,
the Pearson correlation coefficient was calculated per
sample for the 370,699 probes common to both
arrays and passing quality filters. Corroborating pre-
vious studies [3,4,6,8], we found that the per sample
correlation of methylation β-value was high. A 450K
vs EPIC scatter plot of methylation β-value for one
cartilage sample illustrates that the overall correla-
tion was high (Pearson’s r = 0.99) although many
CpGs show substantial differences between arrays
(Figure 1a). The overall per sample correlation
between the same sample assayed on the EPIC
array twice was also high at r = 0.99 (Figure 1b).
However, similar to Logue et al. [3], we also observed
that pairwise correlations between any two samples
from different individuals and arrays were high.
A correlation heatmap showed that samples were
more likely to be similar to other samples assayed
on the same array, rather than to itself run on the
other array (Figure 1c). The separation between
arrays is also seen and is likely a batch effect; never-
theless, we still observe high Pearson’s r across all
samples which implies that a high overall correlation
may not necessarily reflect biological similarity.
Variance and correlation of CpG sites by probe
type
We next examined the correlation between 450K-
and EPIC-generated β values for individual CpG
sites common to the 450K and EPIC arrays. Similar
to prior studies, we found that over 50% of the sites
showed poor correlation (Pearson’s r < 0.2), with
a median per CpG correlation of 0.195 (mean
0.218) (Supplemental Table 1A). Only 3.56% of the
probes showed high (r ≥ 0.8) correlation values. We
also observed that CpG site methylation variance
was generally low across our cartilage samples
(Figure 2a). Poor correlation CpG sites (r < 0.2)
had a significantly lower β value variance than high
correlation (r > 0.8) sites (median variance of 0.0018
and 0.0064, respectively, p < 2.2 × 10−16, Fligner–
Killeen non-parametric variance test). This confirms
that the pattern of low variance sites and poor cor-
relation observed in whole blood [3,4] and placenta
[5] is also seen in cartilage.
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Figure 1. Correlation of normalized methylation β values in 450K vs EPIC arrays. (a) Correlation of β values between the OAK5
cartilage sample assayed on the 450K array and the EPIC array (Pearson’s r = 0.99). (b) β value correlation of the same sample (OAK5)
assayed twice on the EPIC array (Pearson’s r = 0.99). (c) β value correlation heatmap of all 21 cartilage samples assayed on both the
450K and EPIC arrays.
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We sought to determine whether there were
differences in CpG variance and correlation
assayed by probe types in cartilage, as has been
reported in blood [3]. Solomon et al. [4] found
that type II probes had a larger proportion of high
correlation probes in comparison to type I. The
450K array consisted of 28% Infinium type
I probes, whereas the EPIC array consists of 16%
type I probes. We observed that CpG sites assayed
using Infinium type I probes had significantly
lower variance compared to sites measured with
type II probes (Figure 2b; p < 2.2 × 10−16, Fligner–
Kileen test). Furthermore, there was a trend for
type I probes to show lower CpG correlations
compared to type II (Figure 2c).
It has previously been observed that CpG
sites with methylation levels at or close to
extremes (either 0% or 100% methylation)
were more prone to low variance and poor
reproducibility [2,3]. We determined the mean
methylation β-values per CpG in four groups:
probe type I and high correlation, probe type
I and low correlation, probe type II and high
correlation, and probe type II and low correla-
tion (Figure 2d). In the low correlation groups,
regardless of probe chemistry, methylation β
levels were indeed skewed towards 0% or
100%. This skew is more pronounced in type
I probes, although the same trend is also seen
in type II probes.
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Figure 2. Correlation and variance of methylation β values by probe type. (a) Methylation (β value) variance plotted against the
Pearson correlation coefficient across common CpG sites in 450K and EPIC arrays. Variance is the mean of the 450K and EPIC
variances across the 21 samples. (b) Density of β value variance by probe type. Type I probes are shown in red and type II probes are
in blue. (c) Density of Pearson correlation coefficient r by probe type. Type I probes are red, type II probes are in blue, and the
combined Pearson coefficient of both probe types are in green. (d) Mean methylation β values by probe type and correlation group.
CpG sites with low correlation (r < 0.2) are denoted by a dashed line, whereas high correlation (r > 0.8) is marked with solid lines.
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Differences in variance and correlation between
tissue types
To examine if there are differences in DNA
methylation variance and array β value correla-
tions between tissue types, we compared our car-
tilage correlations with those of previously
published 450K vs EPIC datasets. The raw data
from matched 450K and EPIC samples collected
from fresh-frozen paediatric brain tumours and
whole blood from Guthrie cards were accessed
from GEO GSE92580 and GSE86833, respectively.
Data were filtered and processed in the same way
as our cartilage datasets.
The Guthrie card whole blood dataset showed
similar median (r = 0.285) and mean (r = 0.221)
individual CpG correlations to cartilage
(Supplemental Table 1A) and other whole blood
comparisons [3,4], with only 16.68% of probes
having Pearson correlations above 0.8 (Figure 3a,
Supplemental Table 1A). Interestingly, in contrast
to whole blood and cartilage, the majority (58.6%)
of individual CpG sites within the tumour dataset
exhibited high correlation (r ≥ 0.8) between the
two arrays, with a median Pearson’s r of 0.888 and
a mean of 0.695 (Figure 3a-b, Supplemental Table
1A). We further observed that the variance of
individual CpG sites in tumour was higher than
in whole blood and cartilage (Figure 3c). Together,
our data support the hypothesis that low methyla-
tion variance sites tend to have poorly correlating
β values between the two arrays, a pattern we
observe across both probe types and across differ-
ent tissue types.
Given the difference in Pearson r distribution
and mean β variance between cartilage, tumour,
and whole blood, we investigated the degree of
overlap of high (r ≥ 0.8) and poorly correlating
probes (r < 0.2) in the three tissues (Figure 3d,
Supplemental Table 1B). For a specific CpG site,
DNA methylation variance is different between
the three tissue types analysed, such that CpG
sites with low 450K–EPIC correlations are differ-
ent between the tissue types (Supplemental Table
1B). Of 261,995 CpG sites that show low (r < 0.2)
β value correlations between the two arrays in at
least one tissue, only 8.19% were common
between them; this rises to 61% when tumour
data are excluded (Figure 3d). As low correlation
sites are largely distinct between these tissue
types, researchers should not extrapolate data on
450K–EPIC probe correlations from one tissue to
inform another study using different tissue sam-
ples. This is further confirmed by examining the
Pearson’s r distribution in cartilage, tumour, and
blood of 2668 probes recently reported to show
poor correlations (r ≤ 0.2) between arrays in 108
placental samples [5]. Although more than half of
these low reproducibility placental probes also
poorly correlate across the 450K and EPIC arrays
in cartilage and blood samples, the majority
(56.07%) show Pearson correlations of ≥0.8 in
tumour (Figure 3e, Supplemental Table 1C).
Comparison with pyrosequencing
To investigate whether the 450K or EPIC array gave
more accurate measurements, we assayed DNA
methylation of six CpG sites that are present on
both arrays using bisulphite pyrosequencing.
Pyrosequencing is a technique that uses sequencing-
by-synthesis to determine nucleotide polymorph-
isms in DNA and can be used to quantify DNA
methylation after bisulphite conversion of DNA
[7]. The six CpGs were selected to reflect the range
of β value correlations observed in cartilage; twowith
negative correlations and very different β values
between the two arrays (Supplemental Fig. S1),
three with intermediate r values (r = 0.420 to
0.711), and one with high correlation (cg13782176,
r = 0.976). After confirming the accuracy of pyrose-
quencing DNA methylation values using DNA of
known methylation levels, we measured the same
21 cartilage DNA samples that we had matched
450K and EPIC data for (Supplemental Fig. S1 and
S2). Our limited pyrosequencing validation was
inconclusive for deducing which array platform gen-
erated more accurate methylation values; for the two
CpGs that were non concordant between 450K and
EPIC arrays, the pyrosequencing methylation values
for one (cg24555089; Fig. S1A) was more similar to
the 450K values and the other (cg20806296; Fig. S1B)
was more similar to the EPIC values. CpG sites with
similar methylation β values between 450K and
EPIC also yielded similar methylation values mea-
sured by pyrosequencing (Fig. S1C). Prior studies
examining the concordance between the 450K
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Figure 3. Pearson correlation and β value variance of CpG sites across 450K and EPIC arrays in three tissue types. Common samples
assayed on both 450K and EPIC arrays were investigated in whole blood (GEO GSE86833) and paediatric brain tumour (GEO
GSE92580). (a) Percentage of probes grouped by Pearson’s r values. (b) Density plot of Pearson’s r of CpG sites in cartilage (red),
whole blood (green), and whole tumour (blue). (c) Density plot of mean variance (450K and EPIC) in cartilage, whole blood, and
whole tumour. (d) Venn diagram of low correlation (r< 0.2) sites in cartilage, tumour, and whole blood. (e) The grouped distribution
of Pearson’s r values in cartilage, tumour, and whole blood of low correlating probes (r ≤ 0.2) identified in 108 placental samples by
Fernandez–Jimenez and colleagues (ref [5]). (f) Pearson r distribution of differentially methylated CpGs between OA knee and NOF
cartilage samples plotted against Δβ thresholds. The cartilage r distribution for all probes is shown on the left for comparison. (g)
Mean β differences per CpG between 450K and EPIC arrays. Sites with higher mean β values in the 450K array are highlighted in red
and those higher in the EPIC array are highlighted in blue. (h) Per CpG Pearson’s r against absolute mean difference β values
between 450K and EPIC arrays.
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array and pyrosequencing have found that, whilst
showing a good overall correlation, measurements
of some CpG sites do not replicate between the two
methods [9].
For epigenome-wide association studies (EWASs),
the ability to combined 450K- and EPIC-generated
DNA datasets to perform meta-analyses is of great
interest. Themajority of EWASs use both aΔβ thresh-
old and p value threshold for identifying differentially
methylated sites (DMSs), although the Δβ thresholds
vary widely between studies. We performed differen-
tial methylation analysis of 12 NOF cartilage samples
and 9OAknee samples in order to examine if changes
in Δβ threshold altered the probe Pearson’s
r distribution between the 450K and EPIC arrays
(figure 3f, Supplemental Table 1D). For DMSs identi-
fied by both arrays, the mean and median Pearson’s
r increases with increasing Δβ threshold (figure 3f),
presumably due to the selection of probes increasingly
variable methylation levels. Furthermore, the percen-
tage of highly correlating probes (r ≥ 0.8) rising from
61.90% to 90.78% when the Δβ threshold is raised
from 0.1 to 0.2. Thus, when performing a meta-
analysis of data generated by the two arrays, the cor-
relation between the datasets will increase with
increasing Δβ threshold used for identifying DMSs.
Absolute beta differences
We assessed the absolute mean difference in β values
per CpG between the 450K and EPIC arrays and
found that 9244 CpG sites (Supplementary Table 3)
showed greater than 10% absolute mean β difference
between arrays. Of these 9244 sites, there were 5137
CpG sites showing higher values in the 450K array
and 4107 probes with higher values on the EPIC
array (Figure 3g). There was a trend towards sites
exhibiting poor correlation to show larger absolute
mean β differences (Figure 3h). However, similar to
other findings, sites with large differences were not
necessarily those exhibiting low variance [4,5]. There
were 4321 probes with poor correlation (r < 0.2) and
an absolute mean β difference >10% compared to
327 probes with high correlation (r > 0.8) and
a mean β difference >10%. The 4321 probes with
poor correlation and >10% beta difference between
arrays had a variance of 0.0082, whereas the 327 CpG
sites with high correlation and >10% beta difference
had a higher variance of 0.0136. This suggests that
variance does not explain all of the differences seen
between CpG sites measured on Illumina arrays. We
advise excluding the 9244 CpG sites with an absolute
mean β difference >10% frommeta-analyses of DNA
methylation in cartilage tissue measured using the
450K and EPIC arrays.
Discussion
We have shown that whilst overall correlation is
high between the same cartilage samples assayed
on 450K and EPIC arrays, some individual CpG
sites show poor correlation. We found that type
I probes are more prone to low correlation than
type II. Type I probes are more effective than type
II probes at measuring the extremes of methyla-
tion (0% or 100%), but it is at these extremes that
CpG sites show poor correlation. Studies in whole
blood also reported poor individual CpG site cor-
relations [3,4]. These blood studies used different
normalization procedures, suggesting that this
artefact is present regardless of pre-processing
pipeline. Furthermore, this study encompasses
fewer samples compared to previously published
comparisons and the conclusions remain the
same.
Comparisons across tissues reveal that this
trend of poor correlation in low variance sites is
likely due to the inherent variability of DNA
methylation in tissue or cell types rather than the
analysis method. Cartilage tissue has a lower DNA
methylation variance in comparison to whole
tumour and whole blood. This could be in part
due to the composition of cell types within these
tissues; whole blood comprises numerous cell
types and tumour tissue consists of normal and
abnormal cells, factors which contribute to hetero-
geneity in DNA methylation [10–12]. A study
comparing 450K and EPIC in placental tissue,
a tissue comprising multiple cell types, found
that per CpG correlations were high [5]. CpG
sites with poor correlation vary between tissue
types, and therefore, the specification of
a common list of CpGs to exclude would not be
applicable. Researchers studying DNA methylation
in tissues or cell types exhibiting low variance or
extreme methylation values should be aware that
some CpG sites may not be reproducible.
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The 450K array is no longer available; researchers
wishing to assay methylation using BeadChip tech-
nology only have the option of the EPIC array.
Although the 450K array has been discontinued by
Illumina, the array may still have relevance in
ongoing studies and meta-analyses. The compari-
sons between the 450K and EPIC have revealed an
interesting technical artefact in measuring the
methylation of low variance sites with either 0% or
100% methylation levels. However, it is not the first
time that poorly correlated CpG sites have been
described. Comparisons between the 450K and its
predecessor, the Infinium HumanMethylation27
BeadChip, showed strong overall correlations but
weak correlation of some CpG sites [1,13]. Past
studies examining the similarity of measurements
in 450K and pyrosequencing in cell lines and brain
tissue [9,14] have also observed that some CpG sites
do not reproduce. Moreover, comparisons of 450K
to whole-genome bisulphite sequencing showed the
same conclusions [1,15,16] as did reduced represen-
tation bisulphite sequencing [17,18]. Multiple pub-
lished manuscripts have described the correlation of
CpG sites measured using different methods. These
studies were performed in various cell lines and
tissue types. All report a high overall correlation
between DNA methylation of the same samples
measured using different methods. Not all of these
studies commented on individual CpG site correla-
tion; however, manual inspection of the correlation
scatter plots reveals that a subset of CpGs shows
large differences in methylation values between the
platforms being compared [1,15–18]. Altogether,
these studies demonstrate that some CpGs repro-
duce poorly, regardless of sample type or method
used.
It is not often feasible for researchers to validate
CpGs genome wide using a different method and
compare between methods in order to find sites
with poor correlation. However, we and others
have shown that CpG sites with poor correlation
also tend, but not always, to be those with low
variance and very high or very low methylation.
Therefore, it may be beneficial to apply a filter
based on variance and/or percentage methylation,
especially where the methylation level of indivi-
dual CpGs is important for downstream analysis
or if DNA methylation in the tissue type being
studied is relatively homogeneous. For example,
studies investigating the effect of single CpG sites
such as methylation quantitative trait loci (mQTL)
or EWASs may wish to apply additional filters.
Whilst researchers may wish to validate potentially
important CpG sites using a different assay, some
sites may not reliably reproduce regardless of
method. Additionally, it can be difficult to reliably
deduce which method shows the correct methyla-
tion level.
To conclude, we have corroborated past studies
comparing the reproducibility between the 450K
and EPIC platforms. We found that whilst per
sample correlation was high, correlation between
individual CpGs tended to be low in cartilage. We
also report that CpG sites with poor correlation
differ between tumour, whole blood, and cartilage,
and this could be due to differences in DNA
methylation variance between tissues.
Methods
Collection of cartilage samples and DNA
methylation analysis
Cartilage samples were obtained from patients with
knee OA (n = 9) or NOF (n = 12) undergoing total
joint replacement surgery at the Newcastle upon Tyne
NHS Foundation Trust hospitals. The Newcastle and
North Tyneside Research Ethics Committee granted
ethical approval for the collection of the samples (REC
reference number 14/NE/1212), with each donor pro-
viding informed consent. Cartilage was ground as
previously described (Raine et al. 2012 PMID
22586168) and DNA extracted using the E.Z.N.A
Tissue DNA kit (omega BIO-TEK). One microgram
of DNA was bisulphite converted using the EZ DNA
methylation kit (Zymo Research) and quantified
using the 450K and EPIC arrays by Edinburgh
Clinical Research Facility.
Analysis of 450K and EPIC data
Data were processed using the Bioconductor pack-
age minfi [19]. Samples were normalized using the
functional normalization method implemented in
the minfi package. All samples had >95% probes
passing a detection p value of 0.01. Probes with
a detection p value <0.01 were removed from the
analysis. Probes within sex chromosomes were
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removed from the analysis, as were probes pre-
viously reported to be cross-reacting [20] and
probes containing single nucleotide
polymorphisms (SNPs) with a minimum allele
frequency >0.05 in European populations. Only
probes common to the 450K and EPIC array
were selected, this left 372,278 probes (96,514
type I and 275,764 type II) for analysis. Age and
sex covariates of cartilage samples were corrected
for using the removeBatchEffect function in
limma [21]. Correction was performed using
methylation M-values before conversion to methy-
lation β values. Pearson correlation coefficients
were calculated per sample and per CpG site
across both 450K and EPIC arrays. Datasets GEO
GSE92580 (paediatric brain tumour, n = 12) and
GSE86833 (infant whole blood, n = 5) were ana-
lysed using exactly the same method. Correlation
and density plots were generated using the ggplot2
package in R. An online webtool was used to
create the Venn diagram (http://bioinformatics.
psb.ugent.be/webtools/Venn/).
Targeted pyrosequencing
Genomic DNA (750 ng) of the same 21 cartilage
samples was bisulphate converted as above and
eluted in 40 µl elution buffer. Pyrosequencing assays
for the six selected CpGs were designed using
PyroMark assay design software 2.0 (Qiagen); the
primers used are listed in Supplementary Table S2.
Pyrosequencing was performed using PyroMark
Q24 (Qiagen). A calibration curve was made to
confirm the accuracy of the pyrosequencer. For
each CpG, two gBlocks (IDT) of the 300 bp region
surrounding the CpG site of interest were designed
to the bisulphite sequence with either the CpG site
methylated (C) or unmethylated (T); then, the pyr-
osequencing calibration curve was performed using
input DNA of 0–100% methylation with 10% incre-
ments. The calibration curve for cg1925474,
cg13979708, and cg13782176 deviated from the
expected value, and therefore, the methylation
values generated by pyrosequencing were corrected
using the equation x = (y-b)/a, where x is the cor-
rected level of methylation, y is the level of methyla-
tion measured by pyrosequencing, and a is the slope
and b is the intercept of the calibration curve.
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